Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.

The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The user experienced significant hair loss on the scalp, eyebrows, eyelashes, and pubic area, along with itchy, flaky skin and red patches. They have a history of eczema and dermatitis and suspect that stopping shampoo use and taking Ritalin may have contributed to the issue.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.